HomeAbout usHospitalsSearchLogin
Your medical data, safe and secure.
Name
TZP-101
Description
TZP-101 is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the GI tract is severely impaired.
No brand information found.
